Top 10 genomic testing stories in 2022

There’s been an abundance of news surrounding genomic testing over the past year. In light of all the progress that’s been made, Urology Times^® is recapping the top pieces of content on genomic testing from the past 12 months.

10. Panel to discuss new data regarding TP52 mutations and prostate cancer risk

Veda N. Giri, MD, offered a preview of the ENGAGEMENT Study Virtual Genetics Board’s case discussion, which took place on January 18, 2022, and focused on data on TP53 mutations and prostate cancer risk as well as TP53-related management. Watch now.

9. Dr. Spratt discusses ongoing research with Decipher genomic testing

Daniel E. Spratt, MD, discussed the takeaways of the study, “Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Watch now.

8. Awareness, usage of prostate cancer genetic testing are low vs other cancers

Sameer Thakker, MD, discussed noteworthy findings from the Urology Practice study, “Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate and Breast/Ovarian Cancer,” for which he served as a study author. Watch now.

7. Dr. Shore encourages clinicians to implement hereditary cancer risk assessments in their practices

Neal D. Shore, MD, FACS, discusses the takeaways of the study, “Hereditary cancer risk assessment in the community urology practice setting,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Watch now.

6. What is genetic discrimination, and why does it matter?

Individuals who are referred for genetic testing for hereditary cancer or other medical conditions may have concerns about the risks of testing, especially if a mutation is discovered, and how this information might be used by others. Read more.

5. Dr. Stephen Savage discusses molecular testing and unmet needs in prostate cancer

“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” said Stephen J. Savage, MD. Watch now.

4. Study shows feasibility of mRCC treatment selection based on tumor gene expression

Findings from the BIONIKK study published in The Lancet Oncology suggest that biomarker-driven treatment selection based on tumor molecular phenotype may be on the horizon in the treatment paradigm for metastatic renal cell carcinoma. Read more.

3. Dr. Gomella explains the evolving precision medicine paradigm in prostate cancer

In a presentation at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Leonard G. Gomella, MD, explained how the ever-expanding application of genetic and genomic testing has launched the game-changing precision medicine era in prostate cancer. Read more.

2. Dr. Barata stresses significance of tumor sequencing in urothelial carcinoma

Pedro C. Barata, MD, MSc, discussed the importance of tumor sequencing to the implementation of precision medicine for patients with urothelial carcinoma. Watch now.

1. CMS covers ctDNA test for patients with MIBC

The Centers for Medicare and Medicaid Services covered the Signatera molecular residual disease test for use in patients with muscle-invasive bladder cancer, according to Natera, the developer of the assay. Read more.